Showing results (1-10 of 22) with videos related to
Sort By:
Pageof 3
Behavioural Pharmacology|August 24, 2013
Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratiosDavid Hubbard, Uli Hacksell, Krista McFarlandBritish Journal of Pharmacology|April 10, 2003
Analysis of molecular determinants of affinity and relative efficacy of a series of R- and S-2-(dipropylamino)tetralins at the 5-HT1A serotonin receptorJ Tracy Alder, Uli Hacksell, Philip G StrangeThe Journal of Organic Chemistry|June 14, 1996
Regio- and Stereoselective Reactions of 17-Phenyl-18,19,20-trinorprostaglandin F(2)(alpha) Isopropyl EsterCharlotta Liljebris, Björn M. Nilsson, Bahram Resul, et al.Bioorganic & Medicinal Chemistry|March 23, 2005
Isochromanone-based urotensin-II receptor agonistsFredrik Lehmann, Erika A Currier, Roger Olsson, et al.Neurochemical Research|April 1, 2014
On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosisUli Hacksell, Ethan S Burstein, Krista McFarland, et al.European Journal of Medicinal Chemistry|November 23, 2006
Design, parallel synthesis and SAR of novel urotensin II receptor agonistsFredrik Lehmann, Lisa Lake, Erika A Currier, et al.Cytotechnology|November 13, 2008
Chemical genomics: massively parallel technologies for rapid lead identification and target validationUli Hacksell, Norman Nash, Ethan S Burstein, et al.Journal of Medicinal Chemistry|March 31, 2006
Novel potent and efficacious nonpeptidic urotensin II receptor agonistsFredrik Lehmann, Anna Pettersen, Erika A Currier, et al.Bioorganic & Medicinal Chemistry|June 2, 2009
Novel and potent small-molecule urotensin II receptor agonistsFredrik Lehmann, Erika A Currier, Bryan Clemons, et al.Journal of Medicinal Chemistry|February 26, 2009
Design, synthesis, and structure-activity analysis of isoform-selective retinoic acid receptor beta ligandsBirgitte W Lund, Anne Eeg Knapp, Fabrice Piu, et al.Pageof 3